

Biohope Announces Collaboration to Advance Immunobiogram for Renal Transplant

Biohope signs a know-how agreement with Mayo Clinic to advance development and commercialization of its personalized transplant diagnostic device.

MADRID, MADRID, SPAIN, November 3, 2025 /EINPresswire.com/ -- Biohope, a Spanish company specialized in personalized medicine solutions for transplant and autoimmune patients, has signed a know-how agreement with Mayo Clinic, a global leader in medical research and patient care, to advance the development and commercialization of the Immunobiogram, an in vitro diagnostic (IVD) device developed by Biohope and patented in the U.S. and other territories.

“We are thrilled to collaborate with Mayo Clinic, to utilize their expertise in transplant medicine”
Isabel Portero, Biohope's CEO

The agreement grants Biohope access to Mayo Clinic's specialized know-how, and seeks to enhance the clinical validation of the Immunobiogram in the US. This technology aims to optimize immunosuppression management by providing personalized diagnostic insights, potentially reducing rejection rates, infections, and improving graft survival and patient-reported outcomes (PRO).

“We are thrilled to collaborate with Mayo Clinic, to utilize their expertise in transplant medicine,” said Isabel Portero, CEO of Biohope. “This agreement marks a significant step toward our goal of bringing Immunobiogram technology to market and offering transplant patients and clinicians a transformative tool for personalized immunosuppression management.”

About Biohope

Biohope is a biotechnology company dedicated to developing innovative diagnostic solutions for transplant patients. Its patented Immunobiogram technology provides personalized insights into immunosuppression sensitivity, aiming to enhance patient outcomes and quality of life.

Note: Mayo Clinic has a financial interest in the technology referenced in this press release. Revenue Mayo Clinic receives is used to support its mission of patient care, education, and research.

Nila Castello

Biohope Scientific Solutions for Human Health SL

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/863827960>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.